Suspendu

ACTA Prospective, Double Blinded, Multicenter, Randomized, Controlled Trial to Evaluate Mechanical Debridement vs. Radiofrequency-Based Debridement in the Treatment of Articular Cartilage Lesions

0 critères remplis à partir de votre profilVoyez en un coup d'œil comment votre profil répond à chaque critère d'éligibilité.
Ce qui est testé

Mechanical Debridement

+ RF-Based Debridement

Dispositif médical
Qui peut participer

À partir de 18 ans
Voir tous les critères d'éligibilité
Comment se déroule l'étude

Étude thérapeutique

Interventionnel
Date de début : mars 2013
Voir le détail du protocole

Résumé

Sponsor principalSmith & Nephew, Inc.
Dernière mise à jour : 28 mars 2019
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Date de début de l'étude : 8 mars 2013

Date à laquelle le premier participant a commencé l'étude.

This is a non-inferiority, prospective, double blinded, multi-center, randomized, controlled, adaptive study design with enrollment of 82 randomized subjects at up to 13 study sites. Study duration will be until the last subject enrolled reaches 104 weeks post-operative. The study will be comprised of two parts: Part I: Part I will require all Investigators perform 1 to 3 procedures using the Quantum 2 Controller plus Paragon T2 ICW Wand or the WEREWOLF Controller plus FLOW 50 Wand. Investigators must be qualified by training to perform procedures prior to use of either study device. This purpose of Part I will be to minimize variability with the recommended directions for use established in the instructions for use (IFU). Part I subjects will be followed per protocol follow-up requirements, and will be included in the safety population only. These subjects will be additive (to the safety population) to the 82 randomized subjects planned as part of the primary evaluation in Part II. Part II: Part II will consist of 82 randomized subjects. Each Investigator may initiate enrollment of subjects in this part of the study following completion of Part I requirements. The Part II study implements a randomized adaptive study design, whereby an interim analysis will be conducted for sample size re-assessment. There is no intention of reducing the sample size as a result of this interim analysis; however, the sample size may be increased to either establish the non-inferiority and/or may be increased sufficiently to establish superiority depending on the results of the interim analysis.

Sponsor principalSmith & Nephew, Inc.
Dernière mise à jour : 28 mars 2019
Issu d'une base de données validée par les autorités. Revendiquer en tant que partenaire

Protocole

Cette section fournit des détails sur le plan de l'étude, y compris la manière dont l'étude est conçue et ce qu'elle évalue.
Détails du design

148 participants à inclure

Nombre total de participants que l'essai clinique vise à recruter.

Traitement

Cette étude teste un ou plusieurs traitements pour évaluer leur efficacité contre une maladie ou un problème de santé spécifique. L'objectif est de voir si un nouveau médicament ou une thérapie fonctionne mieux, ou provoque moins d'effets secondaires que les options existantes.


Éligibilité

Les chercheurs recherchent des patients correspondant à une certaine description appelée critères d'éligibilité : état de santé général ou traitements antérieurs du patient.
Critères

Tout sexe

Le sexe biologique des participants éligibles à s'inscrire.

À partir de 18 ans

Tranche d'âge des participants éligibles à participer.

Volontaires sains non autorisés

Indique si les individus en bonne santé et ne présentant pas la condition étudiée peuvent participer.

Critères

Inclusion Criteria Subjects MUST meet ALL of the following criteria to be included in the study: Given written informed consent on the IRB/REB approved Consent Form specific to the study, prior to study participation Is male or non pregnant female ≥ eighteen (18) years of age MRI within 9 months of enrollment into this study confirming presence of a medial femoral chondral lesion and medial meniscal tear requiring a partial meniscectomy (as determined by the Investigator) Must present with pain in the index knee of moderate or severe (> 30 mm) as measured by the VAS Must be able to understand English (written and oral) Must be available to come to all study related visits and is physically and mentally willing and able to comply with all post-operative evaluations Must be in general good health (as determined by the Investigator) based on screening assessments and medical history Intra-operative Inclusion Criteria Subjects MUST meet ALL of the following criteria to be included in the study: 1. Arthroscopic confirmation of a lesion requiring treatment meeting the following parameters: Single, treatable chondral lesion, localized to the medial femoral condyle, ICRS Grade 2 with widely displaceable fibrillation or flaps or Grade 3A, < 4cm2 in size Exclusion Criteria Subjects will be excluded from the study, if they meet ANY one (1) of the following criteria: Body Mass Index (BMI) > 40 or index joint pain is due to BMI (as determined by Investigator) Requires bilateral knee surgery Any of the following conditions: active joint infections is immunocompromised, has Sickle Cell disease, has a primary bone disease (e.g., Paget's disease) or disorders that may adversely affect the healing process, or is terminally ill inflammatory rheumatoid arthritis or other systemic inflammatory arthritis (i.e., gout) metastatic and/or neoplastic disease infectious, highly communicable diseases (e.g., active tuberculosis or active hepatitis) coagulation disorder or patient is receiving anti-coagulants documented evidence of a history (e.g. liver testing) of drug/alcohol abuse within 12 months of enrollment into this study diagnosed with a behavioral condition which could affect their ability to accurately comply with the study (e.g. developmental delay, attention deficit disorder, and autism) Any of the following conditions in the index limb or joint: Grade III or greater osteoarthritis as determined by AP radiograph (Kellgren-Lawrence classification) systemic steroid therapy or steroid intra-articular therapy within 4 weeks of enrollment into this study intra-articular viscosupplementation within 3 months of enrollment into this study osteomyelitis, septicemia, or other infections that may spread to other areas of the body fractures, osteocysts or osteolysis recurrent patellar instability (e.g., subluxation or dislocation) severe Varus or Valgus knee deformities (as determined by Investigator) symptomatic tear of the lateral meniscus avascular necrosis synovial disorders (e.g., pigmented villanodular synovitis) previous total or partial meniscectomy requires reconstruction or replacement of medial or lateral meniscus knee instability, malalignment, or patellar tracking dysfunction prior treatment for cartilage repair, including but not limited to ACI, Mosaicplasty and/or marrow stimulation procedures prior knee tendon and/or ligament repair or patellar surgery within 6 months of enrollment into this study Any of the following conditions in the contralateral limb or joint: greater than minimal abnormality as shown by clinical exam and/or imaging scheduled or to be scheduled for surgery over the course of this study involvement causing abnormal ambulation and non-compliance with post-operative rehabilitation guideline The subject has implanted metallic devices (insulin pumps, nerve stimulators, etc), medically implanted clips or other electronically, magnetically or mechanically activated implants that would contraindicate undergoing an MRI scan of the knee The subject has claustrophobia that would inhibit their ability to undergo an MRI scan of the index knee Receiving prescription narcotic pain medication for conditions unrelated to the index knee condition Cardiac pacemaker or other electronic implant(s) Pregnant and/or intending to become pregnant during this study period Participated in a clinical study within 30 days of enrollment into this study, or who is currently participating in another clinical study. Is a prisoner, or is known or suspected to be transient Is involved with Worker's Compensation unrelated to the index knee Is involved with health-related litigation Intra-operative Exclusion Criteria Subjects will be excluded from the study, if they meet ANY one (1) of the following criteria: Has more than 1 chondral lesion requiring treatment Requires concomitant procedures (i.e., anterior cruciate ligament repair, high tibial osteotomy), excluding partial medial meniscectomy Has a medial meniscal tear not requiring treatment Has a medial meniscal tear requiring a procedure other than partial meniscectomy Has a lateral meniscal tear requiring treatment

Plan de l'étude

Découvrez tous les traitements administrés dans cette étude, leur description détaillée et ce qu'ils impliquent.
Groupes de traitement
Objectifs de l'étude

2 groupes d'intervention sont désignés dans cette étude

Cette étude ne comporte pas de groupe placebo. 

Groupes de traitement

Groupe I

Comparateur actif
Mechanical shaver removes areas of damaged tissue

Groupe II

Comparateur actif
Electrical energy removes areas of damaged tissue (Coblation®)

Objectifs de l'étude

Objectifs principaux

Objectifs secondaires

Centres d'étude

Ce sont les hôpitaux, cliniques ou centres de recherche où l'essai est conduit. Vous pouvez trouver le site le plus proche de vous ainsi que son statut.

Cette étude comporte 7 sites

Tucson Orthopaedic Institute

Tucson, United StatesOuvrir Tucson Orthopaedic Institute dans Google Maps

Andrews Research and Education Foundation, Inc.

Gulf Breeze, United States

Orthopaedic Research Foundation, Inc.

Greenwood, United States

Ohio State University

Columbus, United States
Suspendu7 Centres d'Étude